MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells  by Wang, Xiang et al.
FEBS Letters 589 (2015) 490–496journal homepage: www.FEBSLetters .orgMMP-2 inhibits PCSK9-induced degradation of the LDL receptor
in Hepa1-c1c7 cellshttp://dx.doi.org/10.1016/j.febslet.2015.01.007
0014-5793/ 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
⇑ Corresponding author at: 3-19 Medical Sciences Building, Department of
Biochemistry, Mazankowski Alberta Heart Institute, Cardiovascular Research
Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton AB
T6G 2H7, Canada.
E-mail address: cf2@ualberta.ca (C. Fernandez-Patron).Xiang Wang a,f, Evan Berry a,f, Samuel Hernandez-Anzaldo a,f, Difei Sun b,g, Ayinuer Adijiang c,f, Liang Li b,g,
Dawei Zhang a,c,f, Carlos Fernandez-Patron a,d,e,f,⇑
aDepartment of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
bDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada
cGroup on Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Alberta, Canada
dMazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
eCardiovascular Research Group, University of Alberta, Edmonton, Alberta, Canada
f Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
g Faculty of Science, University of Alberta, Edmonton, Alberta, Canadaa r t i c l e i n f o
Article history:
Received 22 October 2014
Revised 8 January 2015
Accepted 12 January 2015
Available online 19 January 2015
Edited by Quan Chen
Keywords:
Matrix metalloproteinase-2
Sterol-regulatory element binding protein




Atherosclerosisa b s t r a c t
Low-density lipoprotein receptor (LDLR) catalyzes the uptake of LDL-cholesterol by liver and periph-
eral organs. The function of the LDLR is antagonized by pro-protein convertase subtilisin/kexin type
9 (PCSK9), which binds to LDLR at the plasma membrane inducing LDLR degradation. Here, we
report that matrix metalloproteinase-2 (MMP-2) interacts with and cleaves PCSK9, as evidenced
by proteomic, chemical cross-linkage, blue native-PAGE and domain-speciﬁc antibodies Western
blot analyses. Furthermore, MMP-2 overexpression renders Hepa1-c1c7 cells resistant to PCSK9-
induced LDLR degradation. The data suggest that pathological MMP-2 overexpression may protect
the LDLR from PCSK-9-induced degradation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Low-density lipoprotein receptor (LDLR) is a cell membrane
lipoparticle receptor that facilitates the uptake of LDL-cholesterol
from plasma into liver and peripheral organs. This function of LDLR
is antagonized by pro-protein convertase subtilisin/kexin type 9
(PCSK9), which is a LDLR ligand that induces LDLR degradation in
lysosomes, thus limiting LDL-cholesterol uptake [1,2]. When intra-
cellular cholesterol levels decrease, the activity of sterol regulatory
element binding protein 2 (SREBP-2) increases, which in turn pro-
motes the transcription of LDLR [3]. Here we report the observation
that matrix metalloproteinase-2 (MMP-2) modulates LDLR protein
bioavailability by interacting with and degrading PCSK9. Giventhat atherosclerosis is directly associated with circulating LDL lev-
els [4], our observation could be important in the pathology of this
disease.
2. Materials and methods
2.1. Recombinant adenovirus construct
Green ﬂuorescent protein (GFP) or human MMP-2-encoding
adenovirus was generated using AdEasy™ system. pOTB7 plasmid
containing MMP2 gene was obtained from ATCC. The MMP2 gene
was excised from the plasmid by XhoI and EcoRI digestion, fol-
lowed by mung bean nuclease digestion to generate blunt ends.
The gene was inserted into GFP tracer-containing adenoviral shut-
tle vector pAdTrack-CMV EcoRV site, and the orientation of the
gene was conﬁrmed by restriction endonuclease digestion. The
generated pAdTack-CMV-MMP2 plasmid was linearized by PmeI
digestion and cotransformed into Escherichia coli BJ5183 with
adenoviral backbone plasmid, pAdEasy-1. pAdTack-CMV-MMP2
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tion. Recombinants were selected for kanamycin resistance and
recombination was conﬁrmed by restriction endonuclease analy-
sis. Finally, the linearized recombinant plasmid (by PacI) was
transfected into HEK293 cells to generate GFP-expressing adenovi-
rus (AdGFP) or mature human MMP-2-encoding adenovirus
(AdMMP-2).2.2. Cell culture
Mouse Hepa1-c1c7 cells expressing LDLR (LDLR-positive) were
cultured in a-modiﬁcation Minimum Essential Medium (aMEM,
Thermo Fisher Scientiﬁc, Nepean, ON) supplemented with 10%
fetal bovine serum (FBS). To overexpress MMP-2, the cells were
transduced with AdMMP-2 or control AdGFP (3 pfu/cell). To study
the effects of MMP-2 overexpression on PCSK9-induced LDLR deg-
radation, the cells transduced with AdMMP-2 or AdGFP were incu-
bated in aMEM with 1% bovine serum albumin overnight before
adding recombinant human (rh) PCSK9 (Creative Biomart, NY,
USA) or vehicle. To study whether MMP-2 catalytic activity was
required for protection, the cells were incubated with the
40 lmol/L MMP-2 inhibitor III (EMD Millipore) for 1 h before add-
ing rhPCSK9.2.3. In vitro reactions
Recombinant human (rh) MMP-2 (EMD Millipore), PCSK9 and
LDLR extracellular domain were incubated in enzyme assay buffer
(25 mmol/L Tris, 5 mmol/L CaCl2, 150 mmol/L NaCl, pH 7.4) at
37 C for 3 h in the presence or absence of the MMP inhibitor,
1,10-phenanthroline (Sigma–Aldrich, Oakville, ON, Canada). For
the chemical cross-linker reactions, rhPCSK9 (4 lg) was incubated
with rhpro-MMP-2 or rhMMP-2 as indicated in the text. Each reac-
tion mix was then divided into two halves, which received either
chemical crosslinker BS3 (5 mmol/L; Thermo Fisher Scientiﬁc,
Nepean, Canada) or vehicle (water) for 30 min. For the PCSK9 cat-
alytic domain cleavage reaction, MMP-2 was incubated with PCSK9
for 3 or 16 h in the presence or absence of 1,10-phenanthroline, as
indicated in the text. Reactions were collected and subjected to
SDS–PAGE, BN-PAGE, gelatin zymography and immunoblot.
2.4. Gelatin zymography
MMP-2 enzymatic activity was determined using gelatin
zymography. Tissue homogenates, cell extracts or in vitro reactions
were subjected to electrophoresis on SDS–PAGE or BN-PAGE gels
co-polymerized with gelatin (2 mg/ml). Following electrophoresis,
gels were washed three times with 2.5% Triton X-100 for 20 min.
Enzymatic reaction was carried out for 16 h at 37 C in enzyme
assay buffer (25 mmol/L Tris, 5 mmol/L CaCl2, 150 mmol/L NaCl,
0.5 mmol/L NaN3, pH 7.4) and gels were stained with Coomassie
Brilliant Blue. Enzymatic activity was visualized as clear bands
against a blue background in the gel.
2.5. Blue native (BN)-PAGE
Gels were cast with equally-sized, discrete layers of 6% and 12%
acrylamide. For gelatin zymography, gels were embedded with
2 mg/ml gelatin. Electrophoresis was performed at room tempera-
ture using Hoefer SE260 (Hoefer, Holliston, MA, USA) with a water
cooling system. For immunoblotting, the BN-PAGE gel was incu-
bated in SDS–PAGE running buffer supplemented with 1% 2-
mercaptoethanol for 10 min before transfer to a nitrocellulose
membrane.2.6. Protein detection
Total protein detection on gels after SDS–PAGE was conducted
using either Coomassie blue or the Zn-Imidazole reverse stain
technique previously described by us [8,9]. Reverse stain was typ-
ically followed by Western blot. Efﬁciency of protein electrotrans-
fer onto membranes was determined using ponceau red stain (for
total protein detection). The expression of speciﬁc proteins after
electrotransfer onto membranes was determined by Western blot.
Cell extracts or in vitro reactions were separated by SDS–PAGE or
BN-PAGE and electrotransferred to a nitrocellulose membrane.
The membrane was probed with primary antibodies against LDLR,
PCSK9 (Abcam, Cambridge, MA, USA) or Anti-6xHis (Abcam, Cam-
bridge, MA, USA) and corresponding secondary antibodies (GE
Healthcare, Buckinghamshire, UK), before being detected using
ECL Western blotting detection reagent (GE Healthcare).2.7. Proteomic analysis
In-gel microwave-assisted acid hydrolysis (MAAH) was com-
bined with liquid chromatography (LC)-electrospray ionization
(ESI) MS/MS for PCSK9 sequence mapping. The gel bands of
rhPCSK9’s prodomain and its cleavage fragment were cut out and
washed twice with 1 ml of water for 5 min. Next, the gel bands
were cut into small pieces and dehydrated using 500 lL of acetoni-
trile (ACN) for 5 min twice. Dry gel pieces were desiccated using
Speedvac (Thermo Fisher Scientiﬁc, Nepean, ON) for 15 min.
120 lL of 12 mmol/L dithiotreitol (DTT) and 40 lL of triﬂuoroacetic
acid (TFA) were added to the vial containing the dried gel pieces.
The vial was immersed in a water bath and placed in a domestic
1200W (2450 MHz) microwave oven. The irradiation time was
10 min. The generated peptide mixture was extracted using
300 lL of 85% ACN/0.1% TFA solution twice, and desiccated using
Speedvac. Reduction and alkylation of the peptide mixture was
performed by using 20 lL of DTT (90 mmol/L) for 1 h at 37 C
and 50 lL of iodoacetamide (200 mmol/L) for 1 h at room temper-
ature. The peptide mixture was then desalted. LC–MS/MS analysis
of the peptide mixtures and database search were performed as
described previously with minor changes [10].
MALDI-TOF mass spectrometric analysis of PCSK9 cleavage
fragments was conducted with an Applied Biosystems Voyager
System 6075 (Protein Facility of the Iowa State University Ofﬁce
of Biotechnology). The cleavage of PCSK9 catalytic domain at the
G;L bonds is proposed from analysis of experimentally observed
peptide masses combined with previously reported cleavage sites
on MMP-2 substrates [5].2.8. Statistical analysis
Results were analyzed using one-way ANOVA (between multi-
ple groups) or t-test (between two groups) (SigmaPlot 11 soft-
ware). All data are reported as means +/ S.E.M.
3. Results
3.1. MMP-2 protects the LDLR from PCSK9-induced degradation
A positive feedback for the SREBP-2 pathway depends on
plasma PCSK9, a circulating LDLR ligand, which binds to the LDLR
extracellular domain and re-routes LDLR from the recycling path-
way to lysosomes where LDLR is degraded [1,2]. In cells that stably
expressed LDLR, addition of recombinant human (rh) PCSK-9
induced degradation of LDLR. However, overexpression of human

































170 kDa - 
130 kDa - 
- LDLR
PCSK9 (µg/well) 0               3.5
AdGFP AdMMP-2 B 
170 kDa - 
130 kDa - 





































Fig. 1. MMP-2 protects the LDLR from PCSK9-induced degradation. (A) Hepa1-c1c7 (LDLR-positive) cells were seeded in complete medium with 10% FBS in 24-well plates.
70% conﬂuent cells were transduced with either AdGFP or AdMMP-2. qRT-PCR and gelatin zymography analyses both demonstrated the overexpression of human MMP-2
activity in AdMMP-2 transduced cells. Results are mean ± S.E.M. n = 3 for each group. (B) 24 h after transduction with either AdGFP or AdMMP-2, the medium was replaced by
serum-free medium supplemented with 4% BSA. 16 h later, rhPCSK9 (3.5 lg/well) or vehicle (water) was added. 4 h later, the cells were collected and lysed. The lysates were
subjected to Western blot with LDLR antibodies. Left: Representative LDLR Western blot traces. Right: Quantitative analysis of LDLR immunoreactivity. Results are
mean ± S.E.M. n = 3–9 for each PCSK9 amount. ⁄P < 0.05 vs. AdGFP (vehicle).
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plementary Fig. 1).
3.2. MMP-2 interacts with PCSK9 and cleaves PCSK9 prodomain
Recombinant human MMP-2 concentration-dependently
cleaved the prodomain of PCSK9 at the Ala44;Leu45 bond (Fig. 2A,
B and Supplementary Table 1); a cleavage site found in other tar-
gets of MMP-2 such as laminin-5 [5]. Complementary SDS–PAGE
band-shift studies using the chemical crosslinker BS3, a homobi-
functional amine-to-amine crosslinker from the family of bis(sul-
fosuccinimidyl)suberates, indicated that MMP-2 and PCSK9
interact (Fig. 2C). Further, MMP-2 binding to PCSK9 resulted in
the release and cleavage of the PCSK9 prodomain by MMP-2. Fur-
ther analysis of in vitro reaction mixtures by blue native (BN)-
PAGE conﬁrmed the chemical cross-linker data, showing that
PCSK9 indeed forms a complex with MMP-2 and the LDLR extracel-
lular domain (Fig. 3). Further, the complex of PCSK9 and MMP-2
had drastically reduced gelatinolytic activity.3.3. Functional connection between MMP-2-mediated cleavage of
PCSK9 and LDLR protection from PCSK9-induced degradation
Cleavage of PCSK9’s prodomain by MMP-2 was evident when
PCSK9 was in a large excess (100 fold) over MMP-2; pro-domain
cleavage did not affect PCSK9’s ability to induce LDLR degradation
in cells (Fig. 4).Our results with the BN-PAGE technique (Fig. 3) suggested that
MMP-2 and PCSK9 may interact and form a complex. To substanti-
ate these ﬁndings, we attempted to quantitatively co-isolate MMP-2
and PCSK9. At PCSK:MMP-2 M ratios of 10:1, the efﬁciency of iso-
lation of the complex of MMP-2 and PCSK9 was systematically
hampered by the degradation of PCSK9 in the presence of active
MMP-2. We failed to isolate MMP-2 bound to PCSK9 using nickel
beads (which strongly bound PCSK9 at the C-terminal 6xHis tag);
addition of a MMP-2 inhibitor prevented PCSK9 cleavage but also
inhibited complex formation (data not shown). However, we suc-
ceeded at isolating PCSK9 together with MMP-2 on gelatin-afﬁnity
beads (which bound MMP-2 avidly) (Fig. 5A). Further analysis of
the reaction mixtures revealed that, when the concentration of
MMP-2 approached that of PCSK9, extensive cleavage of PCSK9
occurred (Fig. 5B and C). We also observed the concomitant
appearance of smaller fragments at 25–30 kDa containing the
PCSK9’s C-terminal domain (as indicated by immunoreactivity
with antibody against the C-terminal 6xHis in rhPCSK9) (Fig. 5C);
this fragment was isolated on nickel beads but failed to bind
MMP-2 (data not shown). Matrix assisted laser desorption ioniza-
tion-time of ﬂight (MALDI-TOF) mass spectroscopy of PCSK9 after
digestion for 16 h at 37 C with APMA-activated pro-MMP-2 sug-
gested two putative cleavage sites both occurring at Gly;Ile bonds
proximal to the C-terminus of PCSK9 (Supplementary Fig. 2) and
that would yield peptides with the experimentally observed
masses values of 33174.81 Da, 22757.56 Da and 8620.60 Da
(Supplementary Fig. 2 and Table 2). Cleavage at Gly;Ile has previ-
ously been documented for other prominent MMP-2 substrates
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Fig. 2. MMP-2 interacts with PCSK9 and cleaves PCSK9. (A) rhMMP-2 and rhPCSK9 were incubated at indicated molar ratios with or without the MMP-2 inhibitor (1,10-
phenanthroline, 100 lmol/L) for 3 h. The reaction mixtures were resolved by SDS–PAGE. Prodomain cleavage by MMP-2 is evident under those reaction conditions. (B)
Sequence of human PCSK9. The prodomain is underlined. The A;L cleavage site in PCSK9 prodomain was determined by in-gel microwave assisted acid hydrolysis combined
with LC-ESI tandem mass spectrometric sequencing after isolation of the prodomain by SDS–PAGE (Supplementary Table 1 shows peptide sequences). The two G;L cleavage
sites are predicted from MALDI-TOF mass spectrometric analysis of mouse PCSK9 incubated for 16 h at 37 C with human MMP-2 (Supplementary Fig. 2 and Table 2 shows
peptide mass data). Amino acid sequence source: http://www.uniprot.org/uniprot/Q8NBP7. (C) rhPCSK9 (4 lg) was incubated with rhpro-MMP-2 or rhMMP-2 (PCSK9:pro-
MMP-2 = 2:1 or PCSK9:MMP-2 = 4:1; mol:mol) for 3 h, with or without 1,10-phenanthroline. Each reaction mix was then divided into two halves, which received either
chemical crosslinker BS3 (5 mmol/L) or vehicle (water) for 30 min. In native PCSK9, the PCSK9’s prodomain is tightly bound to PCSK9’s catalytic domain. The prodomain can
be resolved by denaturing SDS–PAGE and migrates at an apparent molecular weight of 18 kDa. This was prevented by addition of BS3 crosslinker. When either rhMMP-2 or
rhpro-MMP-2 (which was partly active) were added to PCSK9, PCSK9’s prodomain was cleaved. The crosslinker failed to prevent that PCSK9’s prodomain and its cleavage
fragment migrated at their expected molecular weights on SDS–PAGE. The data suggest that MMP-2 binds to PCSK9 releasing and cleaving PCSK9’s prodomain. (⁄) indicate
bands corresponding to MMP-2 or pro-MMP-2.
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and collagen-a1 [5]. Interestingly, once sufﬁciently degraded by
MMP-2, PCSK9 had an impaired ability to induce LDLR degradation(Fig. 5D). However, MMP-2 overexpressing cells may partially
resist PCSK9-induced LDLR degradation in the presence of a
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Fig. 3. MMP-2, PCSK9 and the LDLR extracellular domain interact. Top: BN-PAGE
analysis indicates that rhMMP-2 forms protein complexes with rhPCSK9 and hLDLR
extracellular domain (molar ratio MMP-2:PCSK9:LDLR = 1:18:3). The proteins were
incubated for 3 h at 37 C and the mixtures were resolved by BN-PAGE. Western
blot analysis revealed complex-speciﬁc shifts in rhPCSK9 mobility vs. rhPCSK9. A
decrease in PCSK9 immunoreactivity was evident in the presence of MMP-2.Middle:
BN-PAGE/gelatin zymography (to detect uncomplexed rhMMP-2) indicated that
MMP-2 gelatinolytic activity is inhibited in the presence of PCSK9. Bottom: SDS–
PAGE/gelatin zymography showing total MMP-2 gelatinolytic activity.
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Fig. 4. Limited proteolysis analysis indicates that cleavage of PCSK9’s prodomain by
MMP-2 alone does not block the ability of PCSK9 to induce LDLR degradation. (A)
The reaction was conducted for 3 h at a molar ratio (PCSK9:MMP-2 = 100:1;
mol:mol) which resulted in >80% of PCSK9 prodomain being cleaved. Under these
reaction conditions, less than 1% of the PCSK9 catalytic domain was available for
complex formation with MMP-2 and there was no appreciable degradation of
PCSK9 by MMP-2. (B) The reaction mixture was then added to cells transfected with
either empty plasmid (LDLR-negative) or plasmid expressing LDLR (LDLR-positive).
The cells were collected 4 h later. LDLR protein was detected by Western blot.
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mediated cleavage of PCSK9 may both attenuate PCSK9’s ability
to induce LDLR degradation.
4. Discussion
We have observed that MMP-2 overexpression protects the
LDLR in Hepa1-c1c7 cells from degradation induced by PCSK9
(Fig. 6). In vitro studies using chemical cross-linkage, gelatin-afﬁn-
ity and BN-PAGE separation of protein complexes showed that
MMP-2 binds PCSK9. Moreover, MMP-2 cleaves PCSK9 pro- and
catalytic-domains. Complex formation combined with subsequent
degradation of PCSK9 by MMP-2 can explain why MMP-2 overex-
pression protected the LDLR from PCSK9-induced destruction.
Whether other MMPs interact with PCSK9 in a similar fashion war-
rants investigation.
The current study suggests that the formation of a MMP-
2.LDLR.PCSK9 complex could, together with MMP-2-mediated deg-
radation of PCSK9, increase LDLR bioavailability in the presence of
PCSK9. A consequence of increased hepatic LDLR is LDL-cholesterol
uptake. Increased levels of intracellular cholesterol inhibit further
synthesis and uptake of cholesterol and there is a consequent
decrease in the transcription of SREBP-2 and its gene targets, many
of which encode enzymes involved in cholesterol biosynthesis and
uptake including LDLR [3]. In the current studies, we observed
downregulation of SREBP-2 and target genes in Hepa1-c1c7 cells
overexpressing MMP-2. Further, the same cells exhibited protec-
tion against PCSK9-induced destruction of LDLR. Interestingly,
Mmp2/ mice display strongly elevated hepatic mRNA levels of
SREBP-2 and downstream genes such as HMGCR and LDLR (vs.
WT mice) (unpublished observations). However, in livers from
MMP-2 deﬁcient mice we failed to observe a statistically signiﬁ-
cant reduction in LDLR protein (data not shown). These data sug-
gest that while MMP-2 overexpression may protect, MMP-2
deﬁciency alone may be insufﬁcient to downregulate LDLR cellmembrane bioavailability. The emerging pattern is such that
MMP-2-mediated proteolysis of PCSK9 that is limited to the prodo-
main may not impact LDLR regulation by PCSK9, but in pathologi-
cal conditions where MMP-2 is highly expressed, MMP-2 may bind
as well as cleave PCSK9’s catalytic domain attenuating PCSK9-
induced LDLR degradation. This notion is consistent with the cata-
lytic domain in PCSK9 being a critical determinant of the LDLR-
degrading activity of PCSK9 [6].
We observed that MMP-2 overexpression did not affect basal
levels of LDLR protein but protected the LDLR from exogenous
PCSK9-induced degradation. Does this mean that MMP-2 is selec-
tive for exogenous PCSK9? We think that endogenous levels of
PCSK9 made by the cells (at least under the culture conditions
studied here) are lower than those of exogenous PCSK9 used in
the bioassay of LDLR degradation. In addition, when MMP-2 is
overexpressed there is a convergence of two phenomena: (1)
Downregulation of the SREBP-2 pathway (Supplementary Fig. 1),
which would decrease SREBP-2-dependent endogenous PCSK9
expression. (2) Increased potential for binding and cleavage of
PCSK9, which protects LDLR from exogenous PCSK9-induced deg-
radation. The net outcome of these mechanisms is evidently a lack
of effect of endogenous PCSK9 on basal LDLR protein levels, while
MMP-2 binding and cleavage of exogenous PCSK9 protects the
LDLR.
Establishing the in vivo relevance of the current ﬁndings war-
rants further investigation. Speciﬁcally, the potential involvement
of other proteinases and MMP inhibitors in the regulation of PCSK9
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Fig. 5. MMP-2 degrades PCSK9 and may thus inhibit PCSK9’s ability to induce LDLR degradation. (A) Co-puriﬁcation of rhPCSK9 with rhMMP-2 on gelatin afﬁnity beads.
rhPCSK9 (20 lg) and rhMMP-2 (1 lg) were incubated (in 30 lL of 50 mM Tris, 150 mM NaCl, 1 mM Ca++, pH 7.4) for 2 h at 37 C. Next gelatin beads (10 lL) were added to
afﬁnity capture MMP-2. The suspension was agitated at 37 C for 1 h. After 3 washes with 1 ml of 50 mM Tris, 150 mMNaCl, 1 mM Ca++, an aliquot was saved for zymographic
analysis. The remainder of the beads were boiled in SDS–PAGE loading buffer and resolved on 12% SDS–PAGE. The gel was reverse stained [8,9] to assess total protein content.
(B) Under the conditions described in A, rhPCSK9 degradation was appreciable after as short as 3 h incubation at 37 C. There was a decrease in the amount of intact PCSK9
(band between 55 kDa and 72 kDa) and the appearance of multiple PCSK9 fragments readily detectable at 25–30 kDa by reverse stain. (C) Analysis of reactions between
rhMMP-2 and rhPCSK9 conducted as indicated in B conﬁrmed the cleavage of PCSK9 by MMP-2; which was again prevented by MMP-2 inhibition with ortho-phenanthroline.
Further analysis conﬁrmed the release of a 30 kDa fragment containing the C-terminal domain of PCSK9 by MMP-2 speciﬁc cleavage. The diffuse bands detected by reverse
stain at 25 kDa were not detected by neither of the domain-speciﬁc antibodies suggesting extensive cleavage of PCSK9 at various sites by MMP-2 along the catalytic and C-
terminal domains. (D) Functional assay of PCSK9 degraded by MMP-2 in vitro. For this experiment, rmPCSK9 and rhMMP-2 were allowed to react for 16 h at 37 C
(PCSK9:MMP-2 = 10:1; mol:mol). Next, 4 lg/well of intact PCSK9 (not reacted with MMP-2) or MMP-2-degraded PCSK9 was added to cells cultured on 24 well plates, as










Fig. 6. Proposed model to explain how MMP-2 protects the LDLR from PCSK9-
induced degradation. MMP-2 interacts with PCSK9 and, additionally, has the ability
to cleave and degrade PCSK9; MMP-2 overexpression may thus protect the LDLR
from PCSK9 induced degradation.
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ogy of atherosclerosis is directly associated with the levels of circu-
lating LDL. Receptor-mediated endocytosis by LDLR normally
catalyzes the uptake of LDL lipids by liver and peripheral organs,but this function of the LDLR is antagonized by its ligand, PCSK9.
The binding of PCSK9 to LDLR enhances LDLR degradation, thus
limiting the removal of circulating LDL. By contrast, PCSK9 inhibi-
tors lower LDL levels by blocking PCSK9 function and may thus
protect from atherosclerosis [7]. From the current study, MMP-2
may be protective in atherosclerosis by binding and degrading
PCSK9.
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